MESO

Mesoblast (MESO)

About Mesoblast (MESO)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Details

Daily high

$14.77

Daily low

$14.51

Price at open

$14.72

52 Week High

$21.50

52 Week Low

$9.88

Market cap

1.9B

Dividend yield

0.00%

Volume

100,789

Avg. volume

181,900

P/E ratio

-19.98

Mesoblast News